Clinical trial
GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In…
NCT00488566 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00488566 |
|---|---|
| Title | GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers |
| Official title | Double Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of GSK Drug and the Effect of Single Doses of GSK Drug or Lamotrigine on Resting Motor Threshold in Healthy Volunteers |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug, Other |
| Interventions | GSK drug, Placebo, Lamictal |
| Enrollment | 50 |
| Start date | May 31, 2007 |
| Primary completion | May 31, 2008 |
| Completion | May 31, 2008 |
| First posted | Jun 20, 2007 |
| Last update posted | Oct 26, 2017 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: